1. Bain A, Lavoie C, Rodriguez-Lopez S, Kiddoo D. Renal outcomes of children born with posterior urethral valves at a tertiary center: a 15-year retrospective review. Can Urol Assoc J. 2023;17(4):111-116. doi:10.5489/cuaj.8102
2. Hyman M, Groutz A, Blaivas J. Detrusitor instability in men: correlation of lower urinary tract symptoms with urodynamic findings. J Urol. 2001; 166(2):550-552.
3. Planta D, Gerwinn T, Salemi S, Horst M. Neurogenic lower urinary tract dysfunction in spinal dysraphism: morphological and molecular evidence in children. Int J Mol Sci. 2023;24(4):3692. doi:10.3390/ijms24043692
4. Bingham G, Leslie SW, Rentea RM. Posterior urethral valves. [Updated 2024 May 6]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-.Available from: https://www.ncbi.nlm.nih.gov/books/NBK560881/ 2024.
5. Peters CA, Bolkier M, Bauer SB, et al. The urodynamic consequences of posterior urethral valves. J Urol. 1990;114(1):122-126.
6. McCrery RJ, Appell RA. Oxybutynin: an overview of the available formulations. Ther Clin Risk Manag. 2006;2(1):19-24.
7. Sarhan OM, Wadie B, Al-Kawai F, Dawaba M. Bladder function in children with posterior urethral valves: impact of antenatal versus postnatal diagnosis. Int Braz J Urol. 2022;48(1):78-86. doi:10.1590/S1677-5538.IBJU. 2021.0046
8. Casey JT, Hagerty JA, Maizels M, et al. Early administration of oxybutynin improves bladder function and clinical outcomes in newborns with posterior urethral valves. J Urol. 2012;188(4 Suppl):1516-1520.
9. Norris JJ, Raj JP, Thomas TT, Maleperambil TT, Shubha AM. Effects of oxybutynin in children with posterior urethral valves post fulguration: report in a select cohort of children. J Family Med Prim Care. 2021;10(10): 3706-3711.
10. Ezel Çelakil M, Ekinci Z, BozkayaYücel B, Mutlu N, Günlemez A, Bek K. Outcome of posterior urethral valve in 64 children. Single center experience of 22 years. Minerva Urol Nefrol. 2019;71(6):651-656.
11. Petersen KL, Moore DP, Kala UK. Posterior urethral valves in South African boys: outcomes and challenges. S Afr Med J. 2018;108(8):667-670.
12. Kim YH, Horowitz M, Combs AJ, Nitti VW, Borer J, Glassberg KI. Management of posterior urethral valves on the basis of urodynamic findings. J Urol. 1997;158(3 Pt 2):1011-1016.
13. Greenland JE, Brading AF. The effects of bladder outflow obstruction on detrusor blood flow changes during the voiding cycle in conscious pigs. J Urol. 2001;165(1):245-248.
14. Wani SA, Babu N, Faheem M, Jadhav V, Ramesh S, Deepak J. Early use of bladder relaxant (oxybutynin) in posterior urethral valve patients. Is it justified? Med Sur Urol. 2019;8:222. doi: 10.24105/2168-9857.8.222
15. Misseri R, Combs AJ, Horowitz M, Donohoe JM, Glassberg KI. Myogenic failure in posterior urethral valve disease: real or imagined? J Urol. 2002; 168(4 Pt 2):1844-1848.
16. Sharma S, Joshi M, Gupta DK, et al. Consensus on the management of posterior urethral valves from antenatal period to puberty. J Indian Assoc Pediatr Surg. 2019;24(1):4-14.
17. Abdelhalim A, El-Hefnawy AS, Dawaba ME, Bazeed MA, Hafez AT. Effect of early oxybutynin treatment on posterior urethral valve outcomes in infants: a randomized controlled trial. Journal of Urology [Internet]. 2020 Apr 1 [cited 2024 Oct 17];203(4):826-31. Available from: https://doi.org/10.1097/JU.0000000000000691
18. Lieberman JA. Managing anticholinergic side effects. Prim Care Companion J Clin Psychiatry. 2004;6(Suppl 2):20-23.